Navigation Links
Immune Pharmaceuticals CEO to Chair BIO International Panel "Can Israel Become the Next Biotech Startup Nation?"
Date:4/23/2013

Israel has become a model for high tech entrepreneurship. A country of 8 million people, Israel is home to a vibrant academic biomedical research sector, a global pharmaceutical company and several public biotech companies. Yet, the success of Israel's biotech sector pales in comparison to its high-tech industry. What can be learned from the Israeli Hi-tech Innovation and Entrepreneurship model and how can it be applied to biotech? Which regional partnerships can best leverage Israel's potential? What is the optimal positioning for Israeli Biotech to encourage biopharma companies and investors to step up their involvement?  Complete panel information can be found here.

About Immune Pharmaceuticals Ltd.

Immune Pharmaceuticals Ltd. is an Israel and U.S.-based biopharmaceutical company focused on the treatment of inflammatory diseases and cancer. Immune licensed worldwide rights for systemic indications of bertilimumab from iCo Therapeutics (TSX: ICO) in June 2011, while iCo retained rights to all ophthalmic indications. iCo originally licensed the exclusive world-wide rights to bertilimumab in 2006 from Cambridge Antibody Technology Limited, now part of MedImmune, the global biologics research and development arm of AstraZeneca. Additionally, Immune has licensed from Yissum, the technology transfer company of the Hebrew University of Jerusalem, the injectable applications of the antibody nanoparticle conjugate technology (NanomAbs®). For more information, visit www.immunepharmaceuticals.com.


'/>"/>
SOURCE Immune Pharmaceuticals Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. DSM and DecImmune Therapeutics Sign Agreement to Develop N2 Pathway Blocking Antibody
2. ImmusanTs Epitope-Specific Immunotherapy for Celiac Disease Informs the Potential of Vaccines Against Other Autoimmune Diseases
3. Inovio Pharmaceuticals Universal H1N1 Influenza Vaccine Achieves Protective Immune Responses Comparable to Conventional Vaccine in Phase I Study
4. Arena Pharmaceuticals Initiates Phase 1 Clinical Trial of APD334 for Autoimmune Diseases
5. Two Of The Nations Top Specialists In Lupus, Drs. Swamy Venuturupalli & Daniel Wallace, Join In Expanding Research On Auto-Immune Diseases
6. Research and Markets Announces the Release of Autoimmune Disease Therapeutics to 2016. Targets, Technologies, Therapies, Markets and Opportunities
7. Takeda and Resolve Therapeutics Enter Autoimmune Partnership
8. HYCOR Divests Urinalysis Business to Increase Focus on Allergy and Autoimmune Markets
9. Remique (TM), a Revolutionary Dietary Supplement, Manufactured in FDA Registered Facilities, Receives Raves from Compromised Immune System Sufferers
10. Natural Tree Extract (Larch Arabinogalactan) Shown to Have Statistically Significant Effect in Protecting Immune Health
11. Details of HER-2/neu Class I Antigen Licensed by TapImmune published in Journal of Immunology: Antigen is a naturally processed epitope for breast cancer vaccines.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/7/2017)... IRVING, Texas , Sept. 7, 2017 /PRNewswire/ ... molecular science focused on fulfilling the promise of ... that further validate the benefits of its molecular ... Each study utilized comprehensive genomic profiling plus (CGP+) ... each individual patient,s tumor on a molecular level, ...
(Date:9/7/2017)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a ... will be participating in the Morgan Stanley 15 th ... hotel in New York.  Zimmer Biomet will present on ... A live webcast of the presentation can ... http://investor.zimmerbiomet.com .   ...
(Date:9/6/2017)... 2017  Robert G. Szewc, M.D., is recognized by ... recognition of his contributions to the Medical field.      ... at the practice of Kidney and Hypertension Specialists, which ... hypertension solutions. He has worked in this position since ... as well as expertise in kidneys, hypertension, chronic disease ...
Breaking Medicine Technology:
(Date:9/20/2017)... ... , ... “The Trials I Face to Receive God’s Grace”: a mesmerizing ... and goals to better one’s life through God. “The Trials I Face to Receive ... the wrong places, found a love for writing. Green feels that expressing his feelings ...
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... ... asked at a gathering of executive marketers this week about the value of ... , "Everything that has happened in business has brought us to the ...
(Date:9/20/2017)... ... ... “They Sang At Her Funeral”: a tale of murder that will bring a church ... “They Sang At Her Funeral” is the creation of published author, Annalise Harold, an ... and twelve grandchildren. Before becoming a writer, Annalise had the opportunity to relocate often ...
(Date:9/19/2017)... ... September 19, 2017 , ... DeSola Group, a leading ... Denise Flannery, to its strategic advisory and client development team. , In ... with clients across different industries to develop and implement market-justified strategies, modernize and ...
(Date:9/19/2017)... , ... September 19, 2017 ... ... that Scott McFarland has joined its executive team as the President of ... innovative value-based care management systems and contact centers. , “Scott is a ...
Breaking Medicine News(10 mins):